NCT00146172View on ClinicalTrials.gov

Study Evaluating HKI-272 in Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Breast Neoplasms
Interventions
DRUG

neratinib

HKI-272

Trial Locations (5)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

37203

The Sarah Cannon Cancer Center, Nashville

44195

The Cleveland Clinic Foundation Taussig Cancer Center, Cleveland

63110

Washington University School of Medicine, St Louis

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Puma Biotechnology, Inc.

INDUSTRY

NCT00146172 - Study Evaluating HKI-272 in Tumors | Biotech Hunter | Biotech Hunter